Tumor necrosis factor alpha (TNF-alpha) is a homotrimer protein consisting of 157 amino acids and is mainly generated by activated natural killer cells, T-lymphocytes, and macrophages. TNF-alpha binds to its receptors, mainly TNFR1 and TNFR2 and then initiates a signal pathway for biological functions such as inflammation and cell death. TNF-alpha was found to be expressed in tumors from early stages of disease and it’s continuous presence contributed to chronic inflammation. Numerous studies indicate that TNF-alpha can act directly on cancer cells to promote their pro-metastatic characteristic and functions.
Adalimumab-SAP is a bonded toxin between a biotinylated recombinant humanized antibody to TNF-alpha and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Adalimumab-SAP eliminates cells expressing human TNF-alpha. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Human (Cat. #IT-77)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: Saporin, tumor necrosis factor alpha, TNF-alpha, TNFa, TNFR1, TNFR2, cancer